in this issue
Regions :: Western Europe
Companies eyeing Novartis's animal health business
9:30 AM MST | December 4, 2013 | Natasha Alperowicz
Several companies have emerged as potential buyers of Novartis’s animal health business, according to press reports. Novartis’s CEO, Joe Jimenez, said last month that the company may sell its nonstrategic animal health and OTC businesses if it cannot turn them into businesses of global scale. Combined revenues of the two businesses were $3.7 billion last year, 19% down on the year before. Novartis is working with Goldman Sachs on the review of its portfolio, according to Bloomberg. Bayer, which earlier this year acquired Teva...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee